Ovarian Reserve Test Market Segmented By Follicle Stimulating Hormone (FSH) Testing, Anti-Mullerian hormone (AMH) Testing, Antral Follicle Count Testing, Basal Follicle Stimulating Hormone Testing Type with Blood, Vaginal Swab, Semen, Urine Sample Type
Industry: Healthcare
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Report Type: Ongoing
Report ID: PMRREP32587
According to latest research by Persistence Market Research, ovarian reserve test market is set to witness steady growth during 2021-2031. Demand for ovarian reserve test market will witness steady recovery in short-term, with optimistic growth outlook in the long-run. Ethical issues and less number of skilled surgeons will mean limited opportunities in near future.
However, rising adoption of in-vitro fertilization techniques will provide momentum to the ovarian reserve test market.
Declining follicular pool and oocyte quality specially in the mid to late thirties.
This age-related decline of follicles in the human ovary is supposed to be more than double when numbers fall below a critical figure of 25,000 at ~37.5 years of age. According to World Health Organization (WHO), the number of women age 60 and over will increase from about 336 million in 2000 to just over 1 billion in 2050.
Moreover, safety and efficacy associated with ovarian reserve tests is likely to increase the demand in the near future. Manufacturers are also developing home testing kits for ovarian reserve test also provides easy accessibility and availability for checkups which is likely to rise the demand.
Ovarian surgeries also play an important role in driving the market, since removal of cysts can also result in diminished ovarian follicle in women. Thus, all these factors are likely to increase the market growth in the forecast period.
According to the WHO, fertility issues affect one in ten couples, up to 80 million people globally, and this number is rising.
The conventional AMH blood test can be used any day of the menstrual cycle However, the Elecsys AMH blood test provides more standardized results for assessing ovarian reserves.
Hence, the new test provides healthcare professionals to additional part on the routine clinical practice with more reliable results. This helps to provide streamline opportunity and focus on improving diagnostics in the area of women’s health. This is further to augment the demand for ovarian reserve test methods for women.
However, there has been a decline in the market due to COVID19 Crisis which impacted almost every industry around the globe. The industries and economies were distressed with the mass spread of the infection, resulting in recession and shutting down of the surgeries. Although lock down and shelter-at-home guidelines have meant restricted activities, the market is likely to improve over the course of the assessment period for ovarian reserve test market.
North America is set to witness the fastest growth over the forecast period of 2021-2031 owing to the healthcare system of the U.S. is well-known for its advanced structure and spending. The countries have the highest rate of diagnosis and treatment adoption among all the other countries resulting in a key region for the ovarian reserve test.
Manufacturers are focusing on mergers and acquisitions to fulfill the demands of women overall health.
For instance, in May 19, 2021, Ro Acquires Modern Fertility to Accelerate Its Leadership in Women's Health. Acquisition of high-growth reproductive health company transforms Ro's women's health vertical, laying the foundation for Ro to become the first choice for women's healthcare needs
The Europe ovarian reserve test market is expected to grow at a profitable rate over the forecast period. This growth is owed to the presence of an increasing number of key players and the opportunistic approach to new investments in the field of ovarian reserve test.
Key players in the region are incorporating new assay’s to help clinicians predict poor ovarian response in IVF.
For instance, in 4th June, 2021 Beckman Coulter announced the launch of the first and only test that uses a validated cut-off to aid in the assessment of ovarian response. This new assay helps clinicians predict poor ovarian response in those who plan to undergo controlled ovarian stimulation as part of an in vitro fertilization (IVF) protocol
Moreover, are developing new methods of testing to improve women health.
For instance, Roche introduces a new fertility test for assessment of ovarian reserve for pregnancy. The new Elecsys anti-Müllerian Hormone (AMH) fertility test increases the accuracy of ovarian reserve assessment compared to conventional methods. Thus, it accounts for increase the overall market growth in the region.
Some of the leading manufacturers and suppliers of Ovarian Reserve Test include
Many leading manufacturers are focusing on expanding their business through various advancements in technology and mergers and acquisitions which boosts the market growth in the near future.
By Test Type
By Sample Type
By Distribution Channel
By Region
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.
The report also maps the qualitative impact of various market factors on market segments and geographies.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.
To know more about delivery timeline for this report Contact Sales
